A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy
Annenberg Center for Health Sciences
4 episodes
5 days ago
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.
All content for A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy is the property of Annenberg Center for Health Sciences and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.
Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy
36 minutes 58 seconds
3 years ago
Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.
